von Willebrand Factor Antigen: A Novel On-Treatment Predictor of Response to Antiviral Therapy in Chronic Hepatitis C Genotypes 1 and 4
- 1 August 2010
- journal article
- clinical trial
- Published by SAGE Publications in Antiviral Therapy
- Vol. 15 (6), 831-839
- https://doi.org/10.3851/imp1654
Abstract
Background: Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment. Methods: Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied. Results: High on-treatment levels of vWF-Ag were associated with relapse ( P<0.01) and low on-treatment levels with sustained virological response (SVR). Receiver operating characteristic curve analysis showed that vWF-Ag levels of <300% at week 12 of therapy have a positive predictive value (PPV) of 78% for SVR. In early virological response (EVR) patients, the PPV of vWF-Ag levels <300% at week 12 was 74%. An even higher PPV of 88% in complete EVRs (undetectable HCV RNA at week 12) was observed for the same cutoff value at week 12. Conclusions: On-treatment levels of vWF-Ag can be utilized as an additional predictive marker for response to antiviral therapy. This is especially relevant in EVR patients because EVR alone only has a PPV of 58–72% on SVR, which increased to 74%, when factoring in vWF-Ag levels <300% at week 12, and to 88% in complete EVRs; therefore, measurement of vWF-Ag levels at week 12 is helpful. EVR patients that are above the cutoff values for vWF-Ag that make SVR very probable might profit from an extension of therapy to 72 weeks.Keywords
This publication has 22 references indexed in Scilit:
- Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trialHepatology, 2008
- Interferon-based therapy of hepatitis CAdvanced Drug Delivery Reviews, 2007
- Clearance mechanisms of von Willebrand factor and factor VIIIJournal of Thrombosis and Haemostasis, 2007
- Peginterferon and Ribavirin for Chronic Hepatitis CNew England Journal of Medicine, 2006
- Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infectionJournal of Hepatology, 2006
- Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis CThrombosis and Haemostasis, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Short‐ and long‐term effects of therapy with interferon‐α and pegylated interferon‐α/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis CAlimentary Pharmacology & Therapeutics, 2004
- Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flowBlood, 2004
- Diagnosis, management, and treatment of hepatitis CHepatology, 2004